~ 91ĸƵ Surgical launches the Ultrasonic Dissector*, a significant enhancement to the Versius instrument suite and part of a series of product releases in the Versius Plus offering, which includes vLimeLite† and Versius Clinical Insights
~ The Ultrasonic Dissector is the first advanced energy instrument to be introduced by 91ĸƵ, providing surgeons with a new option for haemostatic coagulation and simultaneous cuttingi with multiple, surgeon-selectable modes to suit each procedural need
91ĸƵ Surgical (91ĸƵ) – the global surgical robotics business – has today announced the launch of the Ultrasonic Dissector, a robotic advanced energy instrument delivering ultrasonic energy to cut and coagulate tissue, as part of its Versius Plus offering.
The Ultrasonic Dissector is the first instrument in the advanced energy instrument range to be introduced by 91ĸƵ. It was developed to deliver ultrasonic energy via a torsional design, and can seal vessels up to 5 mm in diameter, with a mean burst pressure of 908 mmHg,ii – 7.5x that of normal systolic blood pressure.iii The Ultrasonic Dissector promotes haemostatic coagulation and simultaneous cutting with multiple, surgeon-selectable modes to suit each procedural need, supporting surgeons through more complex surgical procedures.
The introduction of the Ultrasonic Dissector to the Versius instrument suite completes a series of product launches made as part of Versius Plus. Versius Plus is designed to facilitate advanced surgical procedures across all specialities. It includes an expanded instrument portfolio, improved console, advanced digital insights, and vLimeLite our fluorescent imaging system for the visualisation of ICG.
Michelle Paknad, President of Global Marketing & US Market Entry at 91ĸƵ Surgical commented: “We’re excited to be bringing advanced energy, in the form of the Ultrasonic Dissector, to the Versius Plus offering. We have listened to the needs of our clinical partners, and I’m delighted that we have been able to develop a practical tool that provides the ability to cut and coagulate tissue through ultrasonic energy, enabling them to perform more complex surgical procedures with Versius and bring the benefits of robotic-assisted minimal access surgery to more patients.”
Mark Slack, Chief Medical Officer and Co-founder at 91ĸƵ Surgical commented: “The introduction of the Ultrasonic Dissector is an important next step in our instrument portfolio. We’ve worked closely with our clinical partners to bring this proven ultrasonic instrument to Versius and are looking forward to seeing the positive impact it will have for surgeons using Versius. As a multifunctional instrument, Ultrasonic Dissector provides enhanced capability to Versius, allowing surgeons to seal blood vessels – supporting them to do more complex procedures with the system and thereby bring more robotic-assisted minimal access surgery to their patients.”
Barrie Keeler, Consultant Colorectal Surgeon and Robotic Lead at Milton Keynes University Hospital NHS Foundation Trust, commented: “Having been involved in the testing and development of the Ultrasonic Dissector, I’m excited to see this significant move forward for Versius. As a colorectal surgeon, ultrasonic tools can help to improve efficiencies and save time while operating, particularly in more challenging procedures by providing enhanced haemostasis and coagulation of fragile tissue. This can give an improved view and allow me to perform the surgery more safely and effectively. The Ultrasonic Dissector is able to integrate seamlessly into our existing Versius workflow, and I look forward to incorporating it into aspects of my surgical practice to strive for improved outcomes for patients.”
Versius has been used to perform over 27,000 surgical procedures globally, with over 130 different surgical procedures undertaken across seven surgical specialties. The system is in routine use for both complex and high-volume low complexity procedures across urology, general surgery, gynaecology, colorectal surgery, and thoracic surgery, with the introduction of the Ultrasonic Dissector set to further support surgeons to perform complex surgical procedures robotically with Versius.
Find out more about the Ultrasonic Dissector here.
ENDS
Notes to editors
*The Ultrasonic Dissector is CE marked. Please check availability of the product in your country with your local sales representative or your local customer service. The Versius System Ultrasonic Dissector Instructions for Use, including the approved indications, contraindications and warnings can be found in the product labelling supplied with each Versius System. The Ultrasonic Dissector is not available for sale in the United States
†vLimeLite is CE marked, please check availability of the product in your country with your local sales representative or your local customer service. The Versius System vLimeLite Instructions for Use, including the approved indications, contraindications and warnings can be found in the product labelling supplied with each Versius System. vLimeLite is not available for sale in the United States.
The Versius Surgical Robotic System
Versius resets expectations of robotic surgery. Versius fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimal access surgery (MAS). The small, portable and modular design of Versius allows the surgeon to only use the number of arms needed for a given procedure.
Biomimicking the human arm, Versius gives surgeons the choice of optimised port placement alongside the dexterity and accuracy of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the open surgeon console has the potential to reduce stress and fatigue and allows for clear communication with the surgical team. By thinking laparoscopically and operating robotically with Versius, patients, surgeons and healthcare professionals can all benefit from the value that robotic MAS brings.
But it’s more than just a robot. Versius captures meaningful data with its wider digital ecosystem to support a surgeon’s continuous learning. Through the Versius Connect app, Versius Trainer and 91ĸƵ clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.
About 91ĸƵ Surgical Limited
91ĸƵ Surgical (91ĸƵ) is a global medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot.
Headquartered in Cambridge, United Kingdom, 91ĸƵ is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.
Founded in 2014, 91ĸƵ Surgical is a private limited company backed by an international shareholder base.
References
i Data on file.
ii Data on file.
iii R M Carey, Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline, ACP, 2017
Supporting documents